NCT01328522View on ClinicalTrials.gov

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

SAR153191 (REGN88)

"Pharmaceutical form:solution~Route of administration: subcutaneous"

Trial Locations (4)

16635

Investigational Site Number 840004, Duncansville

34471

Investigational Site Number 840001, Ocala

75235

Investigational Site Number 840002, Dallas

90211

Investigational Site Number 840003, Beverly Hills

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01328522 - Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients | Biotech Hunter | Biotech Hunter